This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
by Zacks Equity Research
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TRVN) Outperforming Other Medical Stocks This Year?
PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
by Zacks Equity Research
Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
by Zacks Equity Research
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Will Trevena Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Trevena.
Implied Volatility Surging for Trevena (TRVN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena
4 Healthcare Stocks Thriving on Venture Capital Funding
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.
3 Biotech Stocks With Rising Estimates in the Past Month
by Zacks Equity Research
The biotech industry is performing reasonably well. Hence, it is a good idea to select stocks from the sector witnessing positive estimate revisions.
Implied Volatility Surging for Trevena (TRVN) Stock Options
by Zacks Equity Research
Trevena (TRVN) needs investors to pay close attention to the stock based on moves in the options market lately.
Trevena, Inc. (TRVN) Jumps: Stock Rises 11.7%
by Zacks Equity Research
Trevena, Inc. (TRVN) was a big mover last session, as the company saw its shares nearly 12% on the day amid huge volumes.
Trevena Announces FDA Acceptance of Olinvo NDA, Shares Up
by Zacks Equity Research
FDA accepts Trevena's (TRVN) NDA for acute pain drug, Olinvo.
Is a Beat in the Cards for Vertex (VRTX) in Q3 Earnings?
by Zacks Equity Research
Vertex's (VRTX) Kalydeco is expected to generate increased revenues following its label expansion in the third quarter of 2017.
What Makes Trevena (TRVN) a Strong Sell?
by Zacks Equity Research
Trevena (TRVN) has witnessed a significant price decline in the past four weeks, and it has lately seen negative earnings estimate revisions as well.